On April 7, 2026, Novo Nordisk announced a share repurchase program started on February 4, 2026, with plans to buy back up to DKK 15 billion, having already repurchased nearly 10 million B shares valued at approximately DKK 2.6 billion by April 1, 2026. This program, part of their strategy to enhance shareholder value, reflects a positive sentiment towards the company’s financial stability and future prospects.